Litcius/Paper detail

Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study

Juan W. Valle, Arndt Vogel, Crystal S. Denlinger, Aiwu Ruth He, Li‐Yuan Bai, Р. В. Орлова, Eric Van Cutsem, Jorge Adeva, Li‐Tzong Chen, Radka Obermannová, Thomas J. Ettrich, Jen‐Shi Chen, Harpreet Wasan, Allicia C. Girvan, Wei Zhang, Jiangang Liu, Chunlao Tang, Philip J. Ebert, Amit Aggarwal, Samuel McNeely, Brian A. Moser, Joana Oliveira, Roberto Carlesi, Richard A. Walgren, Do‐Youn Oh

2021The Lancet Oncology66 citationsDOI

Topics & Concepts

RamucirumabBiliary tract cancerMedicineBiliary tractInternal medicineChemotherapyOncologyDouble blindCancerPhases of clinical researchGemcitabinePlaceboPathologyAlternative medicineCholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct DisordersPancreatic and Hepatic Oncology Research